NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
68788-7692-02 | 68788-7692 | Prednisone | Prednisone | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 1, 2020 | In Use | |
47335-0475-13 | 47335-0475 | Imatinib Mesylate | Imatinib Mesylate | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 1, 2016 | In Use | |
00069-0486-03 | 00069-0486 | Palbociclib | Ibrance | 100.0 mg/1 | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Oral | Mar 30, 2020 | In Use | |
71335-2387-07 | 71335-2387 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jul 8, 2024 | In Use | ||
68788-4593-02 | 68788-4593 | Methylprednisolone | Methylprednisolone | 4.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 3, 2013 | In Use | |
63323-0762-57 | 63323-0762 | Topotecan Hydrochloride | Topotecan Hydrochloride | 4.0 mg/4mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov 30, 2010 | Mar 18, 2016 | In Use |
70518-1105-01 | 70518-1105 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 10, 2018 | In Use | |
00310-0668-95 | 00310-0668 | Olaparib | Lynparza | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PARP | Oral | Sep 1, 2022 | In Use | |
71779-0125-01 | 71779-0125 | duvelisib | Copiktra | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
16729-0072-12 | 16729-0072 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jun 9, 2015 | In Use | |
25021-0201-66 | 25021-0201 | Mesna | Mesna | 100.0 mg/mL | Ancillary Therapy | Chemoprotective | Detoxifying Agent | Intravenous | Apr 30, 2013 | Aug 31, 2016 | In Use |
57881-0444-10 | 57881-0444 | Ondansetron | Zuplenz | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Oct 8, 2014 | In Use | |
00641-6176-10 | 00641-6176 | Octreotide Acetate | Octreotide Acetate | 500.0 ug/mL | Hormonal Therapy | Somatostatin Analog | Intravenous, Subcutaneous | Apr 4, 2005 | In Use | ||
40051-0606-51 | 40051-0606 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
72603-0325-01 | 72603-0325 | Pemetrexed disodium | Pemetrexed | 100.0 mg/10mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Oct 1, 2024 | In Use | |
63187-0037-09 | 63187-0037 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug 1, 2014 | In Use | |
17856-0759-02 | 17856-0759 | Prednisolone Sodium Phosphate | Prednisolone Sodium Phosphate | 15.0 mg/5mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 20, 2021 | In Use | |
10544-0508-20 | 10544-0508 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 16, 2009 | In Use | |
00603-5336-28 | 00603-5336 | Prednisone | Prednisone | 2.5 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec 21, 2004 | Jul 14, 2017 | In Use |
68071-5242-02 | 68071-5242 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Apr 24, 2020 | In Use | |
51655-0410-53 | 51655-0410 | Prednisone | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 15, 2023 | In Use | |
68727-0712-01 | 68727-0712 | Lurbinectedin | ZEPZELCA | 0.5 mg/mL | Chemotherapy | Alkylating Agent | Adduct Forming Agent | Intravenous | Jun 15, 2020 | In Use | |
70771-1521-07 | 70771-1521 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Apr 30, 2020 | In Use | |
00093-7662-56 | 00093-7662 | Erlotinib | Erlotinib | 25.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Dec 8, 2021 | In Use | |
55045-3848-09 | 55045-3848 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 27, 2007 | In Use |
Found 11765 results — Export these results